US Patent 6977080 Intrapericardial botulinum toxin treatment for bradycardia
Patent 6977080 was granted and assigned to Allergan, Inc. on December, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 14 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Nov, 2023
Golden AI
Edits made to:
Infobox (+9 properties)
Article (+406 characters)
Article
Patent abstract
Methods for treating cardiac muscle disorders, such as cardiac arrhythmias, by administration of a neurotoxin to cardiac muscle are disclosed. Bradycardia can be alleviated for several months by a single intrapericardial or intracardiac injection or infusion of a botulinum toxin. Tachycardia can be alleviated by preganglionic sympathetic nervous system administration of a botulinum toxin.
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Stephen Donovan0
Date of Patent
December 20, 2005
0Patent Application Number
093713540
Date Filed
August 10, 1999
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6977080 Intrapericardial botulinum toxin treatment for bradycardia
Find more entities like US Patent 6977080 Intrapericardial botulinum toxin treatment for bradycardia
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.